Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 May;49(5):442–445. doi: 10.1136/thx.49.5.442

Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.

PMCID: PMC474863  PMID: 8016763

Abstract

BACKGROUND--Pulmonary disease caused by Mycobacterium kansasii is reported in approximately 50 new patients in Britain annually. Rifampicin and ethambutol are effective in vitro but the optimal duration of treatment, and whether isoniazid should also be given, are uncertain. The British Thoracic Society has conducted a prospective, multicentre study of the treatment of this condition with rifampicin and ethambutol given for nine months. METHODS--One hundred and seventy three patients with two or more positive cultures and radiological evidence of disease were recruited via the Mycobacterium Reference Unit (PHLS) in Cardiff from 113 physicians in England, Scotland, and Wales. Rifampicin and ethambutol were given for nine months, other antituberculosis drugs being discontinued once the culture was identified as M kansasii. Patients were reviewed, sputum cultured, and chest radiographs performed before, during, and at regular intervals for 51 months after chemotherapy. RESULTS--The mean (SD) age was 55.5 (11.7) years, 73% were men, and 50% had other lung problems. Cavitation was seen in 88%, bilateral shadowing in 48%, and three or more lung zones were affected in 46%. All cultures were sensitive to rifampicin and ethambutol but resistant to isoniazid and pyrazinamide. One patient who took chemotherapy irregularly still had positive cultures at seven and eight months. Fifteen patients developed positive cultures after the end of chemotherapy; factors which might account for the relapse were identified in eight. Reinfection rather than relapse was suspected in three of the 15. Radiographic improvement stabilised within three years in 80%. CONCLUSIONS--M kansasii pulmonary infection responds well to nine months of treatment with rifampicin and ethambutol but patients who contract this disease have a high mortality rate from other causes. Isoniazid does not appear to be a necessary part of the regimen.

Full text

PDF
442

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn C. H., Lowell J. R., Ahn S. S., Ahn S. I., Hurst G. A. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983 Dec;128(6):1048–1050. doi: 10.1164/arrd.1983.128.6.1048. [DOI] [PubMed] [Google Scholar]
  2. Anderson D. H., Grech P., Townshend R. H., Jephcott A. E. Pulmonary lesions due to opportunist mycobacteria. (Review includes 30 cases of M. kansasii infections). Clin Radiol. 1975 Oct;26(4):461–469. doi: 10.1016/s0009-9260(75)80097-3. [DOI] [PubMed] [Google Scholar]
  3. Banks J., Hunter A. M., Campbell I. A., Jenkins P. A., Smith A. P. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax. 1983 Apr;38(4):271–274. doi: 10.1136/thx.38.4.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bates J. H. A study of pulmonary disease associated with mycobacteria other than Mycobacterium tuberculosis: clinical characteristics. XX. A report of the Veterans Administration-armed forces cooperative study on the chemotherapy of tuberculosis. Am Rev Respir Dis. 1967 Dec;96(6):1151–1157. doi: 10.1164/arrd.1967.96.6.1151. [DOI] [PubMed] [Google Scholar]
  5. Harris G. D., Johanson W. G., Nicholson D. P. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. Am Rev Respir Dis. 1975 Jul;112(1):31–36. doi: 10.1164/arrd.1975.112.1.31. [DOI] [PubMed] [Google Scholar]
  6. Johanson W. G., Jr, Nicholson D. P. Pulmonary disease due to Mycobacterium Kansasii. An analysis of some factors affecting prognosis. Am Rev Respir Dis. 1969 Jan;99(1):73–85. doi: 10.1164/arrd.1969.99.1.73. [DOI] [PubMed] [Google Scholar]
  7. Jones J. S. Mycobacterium kansasii in East Kent. A report of seven pulmonary infections with an environmental study. Br J Dis Chest. 1969 Apr;63(2):83–95. doi: 10.1016/s0007-0971(69)80033-1. [DOI] [PubMed] [Google Scholar]
  8. MARKS J. The design of sensitivity tests on tubercle bacilli. Tubercle. 1961 Sep;42:314–316. doi: 10.1016/s0041-3879(61)80114-1. [DOI] [PubMed] [Google Scholar]
  9. Marks J. Occupation and Kansasii infection in Cardiff residents. Tubercle. 1975 Dec;56(4):311–313. doi: 10.1016/0041-3879(75)90086-0. [DOI] [PubMed] [Google Scholar]
  10. Pang S. C. Mycobacterium kansasii infections in Western Australia (1962-1987). Respir Med. 1991 May;85(3):213–218. doi: 10.1016/s0954-6111(06)80082-x. [DOI] [PubMed] [Google Scholar]
  11. Schraufnagel D. E., Leech J. A., Pollak B. Mycobacterium kansasii: colonization and disease. Br J Dis Chest. 1986 Apr;80(2):131–137. doi: 10.1016/0007-0971(86)90033-1. [DOI] [PubMed] [Google Scholar]
  12. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979 Jan;119(1):107–159. doi: 10.1164/arrd.1979.119.1.107. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES